Overview
There is a need to understand how the data from MAR clinical trials relates to the needs of patients who attend IVF clinics. For example, how are data obtained in clinical studies that enrolled young patients with a normal BMI relevant to the requirements for ARA patients years with a BMI of 32? Real-world data (RWD) studies that highlight the potential benefits of r-hFSH:r-hLH for OS (for example, in women aged 35-40 years with normal ovarian reserve, or advocate individualized fertility treatment approaches that lead to improvements in cumulative live birth rate) are important to inform clinical practice [Bielfeld, 2023; Eggersmann, 2025]. Understanding the role and impact of oocyte quality on implantation failure, and how increasing age affects oocyte quality, is critical for embryologists and MAR [Babayev, 2022; Brieño-Enriquez, 2022]. In addition, awareness of the clinical implications of macromolecules involved in follicular/extrafollicular environments and the cytoskeletal, mitochondrial, and oocyte-derived proteins that contribute to age-related oocyte deterioration [Bomba-Warczak, 2024] has relevance in real-world settings. Being aware of the benefits and drawbacks of treatment ‘add-ons’ such as pre-implantation genetic testing for aneuploidy (PGT-A), and the potential for new diagnostic methodologies are also important for ongoing clinical competence [Taskin, 2024; Handayani, 2024; Popa, 2025; Hochberg, 2025]. Finally, innovations including non-invasive PGT-A, AI algorithms, and non-invasive metabolic imaging [Horta, 2025] require clinical discussion. There is an ongoing and universal requirement for HCPs to individualize patient treatment in MAR in order to optimize their management strategies: this holistic theme applies to every educational activity in this field. Therefore, clinicians need to be equipped with the broad range of physiological and clinical knowledge that enables them to make individual, relevant and appropriate adjustments per patient, to optimize oocyte quality and quantity without negatively impacting safety or efficacy in every cycle of MAR that they undertake [Fatemi 2021; Vaiarelli, 2023]. For this reason, RWD is extremely important, influencing decisions as much as, if not more than, randomized-controlled clinical trial data.
Key Aims
- For fertility professionals to understand the impact of RWD and how it relates to the diverse array of patients in daily clinic settings
- To raise awareness of the differences between data from clinical trials with data from RWD, and how such differences impact patient treatment decisions
- Recognizing that data may be lacking in the most common patient populations in clinic settings (e.g. women >35 years and > 30 BMI) compared with data from younger women who are normoweight
- For fertility professionals to recognize that patient risk factors indicating a requirement for r-hLH before implantation failure include, but extend beyond, advanced reproductive age
- To raise awareness of new technologies (e.g. innovations in PGT-A and other new laboratory screening methodologies), and what they mean for the MAR clinic in daily practice and IVF regimen choice
- Recognizing that MAR best practice is not adopting a standardized ‘one size fits all’ approach; gonadotropin regimens require individualization to achieve success
- For fertility professionals to become advocates for fertility awareness, including MAR, and implement ‘best practices’ for educating society about fertility and optimizing family building
Overall Learning Objectives
After participating in the live session, attendees will be able to:
- ● Understand how to utilize and interpret data from clinical trials to optimize outcomes for the individual patient in front of you
- ● Educate and inform participants on what makes a good RWD trial, including how to construct such a study in your own clinic
- ● Understand which patients require additional r-hLH; what are the risk factors for LH/FSH deficiency?
- ● Discuss the implications of new innovations in PGT-A, especially how they may be implemented and impact treatment decisions in MAR clinic settings
- ● Appreciate that OS protocols always require individualization to best address each patient’s needs
Target Audience
Fertility health professionals working in MAR globally, especially physicians who run clinics, mentor other providers and provide education/awareness/advocacy services for MAR.
European Accreditation Council for Continuing Medical Education Accreditation
The MAR in the Real-World: Treatment Individualization, Virtual, Italy 16/04/2026 – 16/04/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2.0 European CME credits (ECMEC®s).
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications .
“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.amaassn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA. For other countries, please contact the relevant national/regional accreditation authority.
The programme has been developed in partnership with
Med.E.A. is in partnership with
Association of Reproductive Medicine and Surgery (ARMS)
International Federation of Fertility Societies (IFFS)
Spanish Fertility Society (SEF)
Italian Society of Fertility and Sterility Reproductive Medicine (SIFES)
Italian Society of Gynecology and Obstetrics (SIGO Federation)
Société Maroccaine de Médicine de Reproduction (SMMR)
Portuguese Society of Reproductive Medicine (SPMR)
Virtual Workshop
MAR in the Real-World: Treatment Individualization
Thursday, 16 April 2026
From 13.00 to 15.00 CEST
(Central European Summer Time)
Chair
Invited Faculty
Antonio Capalbo
Chieti, Italy
Isabelle Cedrin-Durnerin
Hôpital Jean-Verdier
Hôpitaux Universitaires
Paris-Seine-Saint-Denis, France
Sesh K. Sunkara
UK, London
Christos Venetis
Thessaloniki, Greece
International Committee
Gürkan Bozdağ
REI Clinic
Koc University
Luís Ferreira Vicente
Portugal
Habib Midassi
Sfax, Tunisia
Emre Pabuçcu
Ankara, Turkey
Elsa Viora
Turin, Italy
Scientific Programme
Agenda
Thursday, 16 April 2026
from 13.00 to 15.00
CEST (Central European Summer Time)
13.00 Welcome and introduction
Sesh K. Sunkara, UK
13.05 L1: Why is RWD important for clinical decision making?
Christos Venetis, Greece
13.25 Panel discussion and Q&A
All Faculty and Participants
13.35 L2: Individualisation of ovarian stimulation in ageing and hyporesponse
Isabelle Cedrin-Durnerin, France
13.55 L3: New innovations in screening and how they impact MAR treatment in the clinic
Antonio Capalbo, Italy
14.15 Panel discussion and Q&A
All Faculty and Participants
14.25 L4: Treatment individualization: one size does not fit all
Sesh K. Sunkara, UK
14.45 Discussion and Q&A
All Faculty and Participants
14.55 Conclusions
Sesh Sunkara, UK
15.00 End of the virtual workshop